Coherus Oncology Announces Special Dividend of Biosimilar Contingent Value Rights
Coherus Oncology announced a special dividend distribution of contingent value rights (CVRs) to shareholders, enabling them to benefit from future proceeds from the sale or monetization of the Company's remaining biosimilar assets. This move marks the completion of Coherus's strategic transformation into a focused immuno-oncology company with a pro…